Abstract. The limitations of traditional toxicity testing characterized by high-cost animal models with lowthroughput readouts, inconsistent responses, ethical issues, and extrapolability to humans call for alternative strategies for chemical risk assessment. A new strategy using in vitro human cell-based assays has been designed to identify key toxicity pathways and molecular mechanisms leading to the prediction of an in vivo response. The emergence of quantitative high-throughput screening (qHTS) technology has proved to be an efficient way to decompose complex toxicological end points to specific pathways of targeted organs. In addition, qHTS has made a significant impact on computational toxicology in two aspects. First, the ease of mechanism of action identification brought about by in vitro assays has enhanced the simplicity and effectiveness of machine learning, and second, the high-throughput nature and high reproducibility of qHTS have greatly improved the data quality and increased the quantity of training datasets available for predictive model construction. In this review, the benefits of qHTS routinely used in the US Tox21 program will be highlighted. Quantitative structure-activity relationships models built on traditional in vivo data and new qHTS data will be compared and analyzed. In conjunction with the transition from the pilot phase to the production phase of the Tox21 program, more qHTS data will be made available that will enrich the data pool for predictive toxicology. It is perceivable that new in silico toxicity models based on high-quality qHTS data will achieve unprecedented reliability and robustness, thus becoming a valuable tool for risk assessment and drug discovery.
INTRODUCTION
The gold standard for chemical hazard evaluation has been in vivo toxicology, where the compound is formulated and dosed against rodents or other animals (1) . The high cost of in vivo testing, in terms of time, resource consumption, and animal usage, has confined its usage to testing limited numbers of compounds in a low-throughput manner. It has been estimated that 7,000 animals are needed for each registered pesticide at a cost around tens of millions of dollars in a matter of years (2) . Therefore, the reality is that on one hand, more than a thousand new chemicals and pharmaceuticals are produced each year and thus pose a potential threat to the environment and human health, while on the other hand, in vivo tests can only evaluate a fraction of them (3) . The situation calls for alternative strategies for chemical risk assessment. To advance the state of toxicity testing, the US Tox21 program has initiated a paradigm shift in toxicity testing of chemical compounds from traditional in vivo tests to less expensive and higher-throughput cell-based assays in order to identify key pathways and proteins linked with toxicity end points (4) . The US Tox21 program is aimed at accelerating the development of mechanism-based in vitro screens to better understand the mechanisms of toxicity and to reduce the use of low-throughput, high-cost traditional toxicity testing relied on animal models (5, 6) . The subsequent years observed the successful collaborations that brought together the in vivo experimental expertise of the National Toxicology Program (NTP), quantitative high-throughput screening (qHTS) technology of the National Institutes of Health Chemical Genomics Center (NCGC), and the computational toxicology capability of the US Environmental Protection Agency (4) . Last year, the US Food and Drug Administration joined the US Tox21 program, potentially providing accessibility to human toxicity data for thousands of drugs entered into clinical trials.
Traditional HTS is capable of testing millions of compounds in a week to a month at a single concentration (typically at 10 μM) at a cost of high false positive (FP) and false negative (FN) rates (7) . Certain levels of FP and FN rates for HTS are acceptable as part of a drug discovery project, as long as a few true hits can be confirmed as the starting point of the project. On the contrary, toxicity testing has less tolerance to FPs and especially FNs, since FP results may block or delay a good product from reaching the market, whereas a FN labeling may have serious consequences in regards to the environment or human health. Therefore, a testing system that is more reliable and reproducible than the traditional HTS is highly desirable for the evaluation of adverse effects of chemicals. The qHTS technique, which emerged a few years ago, meets the requirements for toxicity testing (8) (9) (10) , where each compound is tested at multiple (4, (7) (8) (9) (10) (11) (12) (13) (14) concentrations across a four-log unit concentration span, producing a concentrationresponse curve, thus effectively reducing the FP and FN rates. The high-quality data generated from qHTS not only consolidates the ground work on which the risk assessments are based but also lays a solid foundation for computational toxicology. In addition, the qHTS technology improves the data quality without sacrificing the throughput and boosting the capability of screening hundreds of thousands of compounds per week. Given the benefits brought about by qHTS, this technology is not free from technical issues common with HTS (11) or from assay artifacts introduced by, e.g., compound autofluorescence, aggregation, and cytotoxicity (12, 13) .
The toxicity of a chemical can be related directly to its structure; thus, studies of quantitative structure-activity relationships (QSAR) should shed light on understanding the molecular mechanisms of action (MOA) of toxic substances. Machine learning is one of the most frequently used techniques to train computer systems to differentiate actives from inactives within a set of compounds of known activities (14) (15) (16) (17) (18) (19) . Predictive toxicology has incomparable advantages in terms of throughput, cost, and expandability to virtual compounds (1, (20) (21) (22) (23) ; however, reliability and robustness are two major concerns preventing it from being widely applied to risk assessment. The quality of a QSAR model is largely dependent on three factors: data quality, molecular descriptors, and statistical algorithms employed to build the model (24) . Statistical methods are relatively matured and no significant improvement is expected for the near future, yet selecting a suitable method from a pool of statistical methods is not trivial. Support vector machines (SVM) (14, 17) , recursive partitioning (25) , random forest (26) , and Bayesian statistics (27) are the most frequently used nonlinear algorithms, while partial least squares projection to latent structures (28) is the most popular linear method. Both free and commercial molecular descriptors are currently in abundance for model construction. Those molecular descriptors include whole molecule properties (29) , fragment or functional group-based descriptors (30) , atom types (31) , and molecular fingerprints (32). Molecular descriptors contribute tremendously to the predictive power and robustness of a QSAR model. Data quality is another major determinant of the quality of a model, since "garbage-in, garbage-out" should be avoided in the field of machine learning. The data aspect of modeling includes not only the quality and quantity of a data set but also molecular diversity and the distribution or balance of the responses (24) . The newly available qHTS datasets light new hope for computational toxicology by removing the major huddle of data concerns from the path towards reliable and robust toxicity models.
IN VIVO TESTING LIMITS THE EFFICIENCY OF RISK ASSESSMENT
Various animal models have been developed to evaluate acute, subacute, and chronic effects of tested compounds for such end points as oral, dermal, and ocular toxicity, immunotoxicity, genotoxicity, reproductive and developmental toxicity, and carcinogenicity (9, (33) (34) (35) (36) (37) . In vivo animal models offer direct evidence of chemical toxicity in a living organism, but this strength is offset by the weaknesses of lowthroughput and excessive demand of resources (4) . For example, chemicals under toxicology or carcinogenesis evaluations by the NTP take 14 days (in a subacute study) to 2 years (in a chronic study) of exposure in rodents (38) . With tens of thousands of chemicals currently in use, lack of proper safety assessment (39) , and about a thousand new chemicals of commercial and environmental importance emerging each year (3), in vivo testing is becoming inadequate in order to provide timely, much needed safety information. Furthermore, increasing pressure from animal protection coalitions forces people to rethink the policy of using large quantities of animals in toxicology research. Moreover, inconsistent testing results associated with the intrinsic differences of individual animals may prevent researchers from drawing any definitive conclusions on a test compound, especially for orally dosed chronic studies (40) . Lastly, the in vivo testing results of rodents are not readily translatable to humans due to differences in species sensitivity (9) . In order to bridge the gap between high-dose toxicity in rodents and low-dose risks in humans, physiologically based pharmacokinetics (PBPK), a mathematic modeling technique, may be needed to minimize the cross-species differences in physiology (41, 42) . PBPK research has exhibited some encouraging capabilities in profiling the human PK of a compound from mouse PK data; however, PBPK is still a long way away from being able to deliver consistent predictions (43) .
ROBOTIC CELL-BASED QHTS PLATFORM DELIVERS HIGH THROUGHPUT AND HIGH QUALITY
The HTS technique, originally developed by the pharmaceutical industry to identify bioactive compounds from huge corporate compound libraries, greatly enhanced the throughput of biological assays (44, 45) . The trade-off of high throughput of the traditional single concentration HTS is its high FP and FN rates (7) . In order to overcome this shortcoming of traditional HTS, a new technology, quantitative HTS, was developed by the NCGC (46) and has matured and been widely applied in subsequent years (8, 9, 13, (47) (48) (49) (50) (51) (52) (53) (54) (55) . The cytotoxicity profiling of the NTP library of 1,408 environmental chemicals against 13 human and rodent cells and cell lines clearly exhibited the robustness and reproducibility of the qHTS technique, where three independent runs on the HepG2 cells produced a high correlation of r 2 =0.87 (9) . In addition to the inherent benefits of greatly improved data quality, qHTS can either use various human cell lines to make the assay results more relevant to human toxicology or use rodent cell lines to improve the understanding of relationships between in vitro data and in vivo rodent toxicity accumulated over the last two decades. Another advantage of using cell-based assays is that the permeability of testing compounds is already taken into account. By combining the cell-based toxicity data with the PK profile of the tested compounds (56) , their oral toxicity might be reliably predicted.
The Tox21 program has acquired a new robotic system ( Fig. 1) , which is located at NCGC, and is expected to greatly accelerate the transition of the Tox21 program from its pilot phase to its production phase. During the production phase, over 10,000 chemicals, of which approximately two thirds are environmental chemicals and the rest pharmaceuticals, will be screened against a wide spectrum of assays in order to cover as many known relevant pathways as possible for toxicity testing.
THE HISTORY OF COMPUTATIONAL TOXICOLOGY
It has long been recognized that the biological activity, including toxicity of a chemical, resides somewhere in the structure of the chemical (57) , yet it continues to remain a challenge to fully understand the mechanism of toxicity at the cellular and molecular level. In the early 1990s, the National Institute of Environmental Health Sciences initiated a Predictive Toxicology Evaluation (PTE) project, aiming at a rigorous and objective evaluation on the performance of predictive toxicology (58) . In the first round of the PTE experiment (PTE-1), the PT community was challenged to predict the carcinogenicity of 44 chemicals, and in the following PTE-2 practice, a set of 30 different compounds were supplied by the NTP for prediction (59) . The training set of 313 NTP chemicals were classified for each sex-species experiment into four overall levels of evidence, namely clear evidence, some evidence, equivocal evidence, and no evidence, according to the long-term chemical carcinogenesis experiments (60) . The PTE results were intensely reviewed (61) (62) (63) (64) (65) (66) , and some consensus was reached, including QSARbased models were outperformed by models using biological attributes (58) . Consequently, the best QSAR model using inductive logic programming could only achieve a predictive accuracy of 63 % in a 5-fold cross validation (67) . Why did QSAR approaches fail in predicting chemical carcinogenesis?
PROBLEM COMPLEXITY AND APPLICABILITY DOMAIN
One of the most frequently asked questions in QSAR research is how large a training set is needed to ensure a reasonable predictive model. The answer to this question depends on many factors, among which the most important determinant is the complexity of the concept to learn.
QSAR is a special case of machine learning. Machine learning is to train computer systems with existing knowledge, such as measured toxicity of compounds in a training set, and the learners then make predictions on the basis of the experience built over the learning materials. The concept to learn has different levels of complexity, as demonstrated in Fig. 2 ; thus, the size of a training set required to learn these concepts also varies. Two data points can define a straight line in space (Fig. 2a) ; a few more data points may be needed to reinforce the linear assumption without considering errors. Nonlinear responses add more difficulties to the model, but a smart learner can figure out the relationships that are hidden in a dataset governing the concept through transforming a nonlinear problem to a linear one in feature space, as long as the problem is analytically solvable (Fig. 2b) . A nonlinear problem with a high level of random noise (Fig. 2c) requires a larger training data set in order to be simulated. Biological data are usually nonlinear, multi-dimensional, and can be highly variable from experiment to experiment (68); therefore, it is less likely to achieve a reasonably reliable and robust QSAR model with less than a thousand balanced training compounds, although the optimum size of a training set also depends on the types of descriptors and statistical methods (69) .
Mechanisms of chemical carcinogenicity have been thoroughly investigated, and a considerable amount of research has been published over the past few decades (70) . Chemical carcinogens can be divided into genotoxic (or DNA-reactive) carcinogens and nongenotoxic carcinogens. Many classes of chemical carcinogens, such as alkylating agents, acylating agents, and arylaminating agents, have been found to react with different sites of DNA bases, but not all DNA-reactive chemicals are carcinogens, since cells possess a variety of DNA repair processes (71) (72) (73) . Mechanisms of nongenotoxic carcinogens are also complicated, which include peroxisome proliferator effects (74), cytotoxicity, immunosuppression, induction of hormonal imbalance, and oxidative stress (70) . In conclusion, chemical carcinogenicity is extremely complicated for machine learning. As a result, a training set of 313 compounds in the PTE experiment is far from sufficient for the construction of any predictive model. Any attempt to learn a complex concept with limited training sets can lead to failure, which can partially explain the failure of the QSAR modeling efforts in PTE-1 and PTE-2.
One way to overcome the local effects associated with limited training data is to build a local QSAR model and to confine its usage to the coverage of the training data that the model is based on. As illustrated in Fig. 3 , a simpler concept may be embedded in an overall complicated concept. In such a case, a local model can be valid as long as it is applied within its applicability domain (AD), defined by the structural space spanned by the training data (75) . Once the AD of a QSAR model is defined, the accuracy or confidence of its predictions can be estimated by the distance to model of individual test compounds (76, 77) . To prevent predictive errors introduced by extrapolations, one should avoid applying a local model outside of its AD. Multiple local models might be built to cover different regions of a complex concept, but misclassifying a test sample to the wrong local model may ruin the predictive performance. Another strategy to deal with complex concepts is to simplify them through decomposition.
DECOMPOSE COMPLEX MOA TO PATHWAYS AND ENZYMES
Assuming a compound exhibits adverse effects by interacting with molecular targets A, B, or C, subsequently the QSAR model has to cover the chemical space representing the ligand binding sites of three different targets. This kind of QSAR model generally requires a larger training dataset than individual QSAR models for each of the three targets (78) . The dilemma here is that a complex MOA requires a large training set to decipher the underlying complexity, whereas the data available for complex MOAs, such as in vivo toxicity, for training purposes are limited (62) .
Most of the toxicological end points are entangled with multiple mechanisms, pathways, and enzymes, as discussed in carcinogenicity. The complex toxicological end points can often be broken down into a few specific pathways in specific Fig. 2 . a-c Graphics illustrating the increasing complexity level of concepts Fig. 3 . A picture elucidating the concept of applicability domain (AD) and the increased deviation outside of AD target organs (57) . The more detailed and specific information on the molecular targets behind the toxicity is revealed, the more likely the MOA of the chemical toxicity can be understood. The US Tox21 program aims to identify such in vitro assays that can detect perturbations in cellular pathways that are expected to contribute to or result in adverse effects (4, 79) . To decipher chemical toxicity at the cellular and molecular level, the Tox21 program has established in its pilot phase a number of pathway-or target-based assays with initial focuses on stress response and nuclear receptor signaling pathways. The selection of stress response pathway assays is based on the premise that compounds inducing one or more stress response pathways are more likely to exhibit in vivo toxicity than those that do not (80) . Examples of such stress response pathway assays include assays that can detect compounds capable of inducing oxidative stress by activating the antioxidant response element via the Nrf2 signaling pathway (Shukla et al., MS in preparation) (81), DNA damage response by inducing differential cytotoxicity in several different DNA repair deficient DT40 chicken isogenic cell clones compared to the wild-type cells (82) , mitochondrial damage by causing changes in mitochondrial membrane potential (Sakamuru et al., MS in preparation), inflammatory response by activating the NFκB (Toll-like receptor) signaling pathway (83) or inducing TNFα production (47), hypoxic response by activating hypoxia inducible factor-1 alpha activity (84) , cardiotoxicity by inhibiting the human ether-á-go-go-related gene (hERG) potassium channel (85) , and apoptosis by activating the caspase-3/7 pathway (54). Endocrine disruption-related toxicity is a major concern for environmental chemicals. The Tox21 pilot phase collection of approximately 3,000 compounds has been screened against ten human nuclear receptors including ERα, AR, GR, TRβ, PPARδ, PPARγ, FXR, LXR, RXR, and VDR (13).
IMPROVED PREDICTIVE PERFORMANCE ACHIEVED BY USING QHTS DATA
The qHTS technology has not only helped to increase the quantity but also improve the quality of biological data, which has deterred the development of reliable QSAR models (24, 86) . The qHTS technology, combining the strength of higher-throughput and lower experimental errors, has provided the QSAR community with several good quality datasets, including the inhibition data of five isozymes of human cytochrome P450 (CYP450) (87) , hERG (85), cytotoxicity, etc. These valuable datasets are publicly available through PubChem (88, 89) . QSAR models built on the basis of the qHTS data assumed higher reliability and better coverage of the chemical space (18, (90) (91) (92) . The SVM classification models trained using the CYP450 data achieved high predictive accuracies of between 0.85 and 0.93 over the equal-sized test sets for all five CYP450 isozymes, as measured by the area under the receiver operating characteristic curves (AUC-ROC) (92) . The CYP450 models constructed from over 6,000 drug-like small molecules exhibited high predictive accuracies of AUC-ROC (between 0.78 and 0.85) when used to predict a collection of non-druglike environmental toxins, such as pollutants, food additives, and pesticides (Sun et al., submitted for publication). The unexpected high predictive accuracies over the dissimilar compounds can be attributed largely to the high quantity of qHTS training data measured under the same conditions and atom typing descriptors, which greatly expanded the coverage of chemical space and the AD of the resulting models.
RECONNECT IN VITRO DATA AND IN VIVO TOXICITY
In vitro data generated via qHTS campaigns are tied to specific cell types and/or pathways; thus, these activities may or may not be directly related to any toxicological end points, which is more meaningful to public health. In order to reconnect in vitro data with in vivo toxicities, many efforts have been made over the past few years. In order to improve the efficiency of detecting toxicity mechanisms, we (54) measured the cell viability and caspase activation of 13 different cell types against the NTP library of 1,408 compounds. The assay results were later analyzed using an unsupervised k-means clustering algorithm to maximize Dunn's index, a measure of cluster quality in terms of internal consistency (93) . The results suggested that a set of six assays could achieve 94 % of the clustering resolution achieved by all 26 assays (54) . By removing redundant assays, the same compound MOA can be reached at a significantly reduced cost. Due to our limited understanding of toxicity mechanisms, it is difficult to determine a priori which assays are relevant for a given toxicity end point. In another attempt, DiMaggio et al. biclustered the in vitro assays by iterative optimal reordering of the 309 ToxCast compounds and the 524 assays in a heat map to determine whether there existed correlative changes in the chemicals over particular subsets of assays (94) . The biclustering practice on in vitro data produced reasonable clusters on assay targets and types. The sparse in vivo data set was processed similarly, and the toxicity end points were observed to cluster according to animal species and similar physiological attributes (94) . Then the in vitro and in vivo data were cross-linked via regularized logistic regression, resulting in the conclusion that the CYP assays exhibited a specificity for the liver end points while estrogen/androgen nuclear receptors were indicators of the reproductive end points (94) . These results suggest a promising opportunity to reconnect in vitro and in vivo assays through a set of compounds without any a priori knowledge of assay targets and toxicity end points; however, quantitative relationships between in vitro and in vivo results cannot be derived using this approach. In vitro data can also be used in combination with chemical descriptors to enhance the predictability of a QSAR model. Tropsha's group observed that the predictive accuracy of rodent carcinogenicity using k-nearest neighbor (kNN) QSAR models significantly improved to 72.7 % when combining chemical descriptors with human cell viability assay data from the 62.3 % obtained using chemical descriptors alone (95) . The same group included the cell viability qHTS concentration-response data in 13 cell lines as biological descriptors when constructing QSAR models, and a similar trend of improving model accuracy was obtained in their kNN and random forest QSAR models for the prediction of rodent acute toxicity (96) . As these approaches have achieved limited success in making use of in vitro assay data to enhance our understanding of in vivo toxicity, significantly more work is needed to meet the ultimate goal, i.e., to design a set of in vitro assays to produce results that can be used as good predictors of in vivo toxicities. As a result of the Tox21 program entering its production phase, more cell-based qHTS data will become available to the public domain, and the gap between the in vitro assays and in vivo activities will be mitigated gradually.
SUMMARY
Rapid advances in molecular and cellular biology in the last two decades declare the advent of a new era in chemical toxicity testing. The newly emerged qHTS technology enables the capacity of testing tens of thousands of compounds per week with unprecedented quality and reproducibility. The US Tox21 program routinely screens chemicals of environmental and human health importance using cell-based qHTS assays, aiming to identify key pathways or molecular targets relevant to toxicity. The qHTS assays have shed light into understanding the events leading to toxic responses at the level of cellular and molecular interactions and reactions. The qHTS assay results of significantly improved quality and quantity will pave the road toward robust and reliable QSAR models. The QSAR models based on the qHTS data have demonstrated higher predictive accuracies and broader coverage of chemical space. Computational toxicology plays an important role not only in predicting the toxicity of a compound but also in prioritizing compounds for further testing, systematically evaluating in-depth toxicology, suggesting safer chemicals to use in the environment, in food, or in the pharmaceutical industry, and also in elucidating the mechanisms by which chemicals exert their toxic action on living organisms. Primary successes have been achieved on modeling in vivo toxicity using in vitro assay results and on cross-linking in vivo and in vitro assay results. With the Tox21 program entering its production phase, we are closer to our goal of reducing and ultimately replacing animal based in vivo testing with cost efficient in vitro assays for chemical risk assessment.
